Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes Discussion
Type 1 Diabetes
New insulin Lilly Peglispro
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="tim2000s" data-source="post: 738729" data-attributes="member: 30007"><p>The other thing to be aware of are these sentences at the foot of the Lilly Release detail. It's not all plain sailing...</p><p></p><p>Results of these two trials also showed patients taking BIL experienced changes in lipid parameters, <strong>including a small but statistically significant increase in triglycerides in both trials</strong>. In IMAGINE-3, there were <strong>small but statistically significant reductions and increases, respectively, in HDL (high-density lipoprotein) cholesterol and LDL (low-density lipoprotein) cholesterol in patients taking BIL compared with those taking insulin glargine</strong>. In addition, IMAGINE-3 showed patients taking BIL experienced <strong>small but statistically significant increases in systolic and diastolic blood pressure compared to insulin glargine (less than 2 mmHg mean difference at 52 weeks)</strong>. Statistically significant differences in HDL and LDL cholesterol and blood pressure were not observed in IMAGINE-1. There were no major adverse cardiac events (MACE) in IMAGINE-1, and <strong>in IMAGINE-3, the MACE+ (cardiovascular death, non-fatal stroke, non-fatal MI and hospitalization due to unstable angina) event rate was lower for patients taking BIL compared with those taking insulin glargine</strong>.</p><p></p><p>In both trials, <strong>treatment with BIL was associated with a statistically significant higher incidence of patients with greater than three times the upper limit of normal range in the liver enzyme ALT (alanine aminotransferase) compared with patients taking insulin glargine</strong>. No cases of severe liver injury (Hy's Law) occurred in either of the trials. <strong>In a subset of patients whose liver fat was measured using MRI imaging, BIL-treated patients had a statistically significant increase in liver fat compared to insulin glargine.</strong></p><p></p><p>In both trials, there were s<strong>ignificantly more injection site reactions observed in patients taking BIL</strong> compared to those taking insulin glargine.</p></blockquote><p></p>
[QUOTE="tim2000s, post: 738729, member: 30007"] The other thing to be aware of are these sentences at the foot of the Lilly Release detail. It's not all plain sailing... Results of these two trials also showed patients taking BIL experienced changes in lipid parameters, [B]including a small but statistically significant increase in triglycerides in both trials[/B]. In IMAGINE-3, there were [B]small but statistically significant reductions and increases, respectively, in HDL (high-density lipoprotein) cholesterol and LDL (low-density lipoprotein) cholesterol in patients taking BIL compared with those taking insulin glargine[/B]. In addition, IMAGINE-3 showed patients taking BIL experienced [B]small but statistically significant increases in systolic and diastolic blood pressure compared to insulin glargine (less than 2 mmHg mean difference at 52 weeks)[/B]. Statistically significant differences in HDL and LDL cholesterol and blood pressure were not observed in IMAGINE-1. There were no major adverse cardiac events (MACE) in IMAGINE-1, and [B]in IMAGINE-3, the MACE+ (cardiovascular death, non-fatal stroke, non-fatal MI and hospitalization due to unstable angina) event rate was lower for patients taking BIL compared with those taking insulin glargine[/B]. In both trials, [B]treatment with BIL was associated with a statistically significant higher incidence of patients with greater than three times the upper limit of normal range in the liver enzyme ALT (alanine aminotransferase) compared with patients taking insulin glargine[/B]. No cases of severe liver injury (Hy's Law) occurred in either of the trials. [B]In a subset of patients whose liver fat was measured using MRI imaging, BIL-treated patients had a statistically significant increase in liver fat compared to insulin glargine.[/B] In both trials, there were s[B]ignificantly more injection site reactions observed in patients taking BIL[/B] compared to those taking insulin glargine. [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes Discussion
Type 1 Diabetes
New insulin Lilly Peglispro
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…